High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma by Lee, Jeeyun et al.
High-Throughput Mutation Profiling Identifies Frequent
Somatic Mutations in Advanced Gastric Adenocarcinoma
Jeeyun Lee
1, Paul van Hummelen
2, Christina Go
2, Emanuele Palescandolo
2, Jiryeon Jang
1,H a
Young Park
3, So Young Kang
3, Joon Oh Park
1, Won Ki Kang
1, Laura MacConaill
2, Kyoung-Mee Kim
3*
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Center for Cancer
Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Pathology, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Abstract
Background: Gastric cancer is one of the leading cancer types in incidence and mortality, especially in Asia. In order to
improve survival, identification of a catalogue of molecular alterations underlying gastric cancer is a critical step for
developing and designing genome-directed therapies.
Methodology/Principal Findings: The Center for Cancer Genome Discovery (CCGD) at the Dana-Farber Cancer Institute
(DFCI) has adapted a high-throughput genotyping platform to determine the mutation status of a large panel of known
cancer genes. The mutation detection platform, termed OncoMap v4, interrogates 474 ‘‘hotspot’’ mutations in 41 genes that
are relevant for cancer. We performed OncoMap v4 in formalin-fixed paraffin-embedded (FFPE) tissue specimens from 237
gastric adenocarcinomas. Using OncoMap v4, we found that 34 (14.4%) of 237 gastric cancer patients harbored mutations.
Among mutations we screened, PIK3CA mutations were the most frequent (5.1%) followed by p53 (4.6%), APC (2.5%), STK11
(2.1%), CTNNB1 (1.7%), and CDKN2A (0.8%). Six samples harbored concomitant somatic mutations. Mutations of CTNNB1
were significantly more frequent in EBV-associated gastric carcinoma (P=0.046). Our study led to the detection of
potentially druggable mutations in gastric cancer which may guide novel therapies in subsets of gastric cancer patients.
Conclusions/Significance: Using high throughput mutation screening platform, we identified that PIK3CA mutations were
the most frequently observed target for gastric adenocarcinoma.
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Introduction
Gastric cancer is the fourth most common cause of cancer
worldwide, and the second leading cause of cancer deaths
worldwide. The American Cancer Society has estimated that
21,000 new cases of gastric cancer diagnosed in the United States
in 2012, and that more than 10,000 Americans would die of
gastric cancer during the year. [1] Despite recent efforts in multi-
modality therapeutic approach for advanced gastric cancer,
approximately half of patients who undergo curative surgical
resection still develop loco-regional or distant metastases and die
from the disease.[2–4].
Recently, an increased understanding of the biological driver
events for solid tumors, coupled with advances in technologies
used to detect somatic cancer alterations, has led to a rapid
progress in personalized cancer medicine programs at several
cancer centers. [5,6] Gastric cancer is a heterogeneous disease
with multiple environmental etiologies and aberrant pathways of
carcinogenesis. Nevertheless, precise molecular subclassifications
as well as a full landscape of oncogenic driver mutations have
not been defined yet in gastric cancer. One of the known
gastric cancer subtypes is EBV-GC which has distinct clinico-
pathologic features, and a relatively favorable prognosis. [7,8]
We have adapted a high-throughput genotyping platform to
determine the mutation status of a large panel of known cancer
oncogenes and tumor suppressor genes to identify the subsets of
gastric cancer patients who may potentially benefit from
targeted therapy (Table 1). [5] Procurement of fresh frozen
tissue specimens is not always feasible in cancer patients; and
thus, a high throughput platform which reliably genotypes
cancer using paraffin embedded tissue samples is needed until
more reliable rare cell sequencing becomes available in reality.
The genotyping platform, termed OncoMap, employs mass
spectrometric-based genotyping technology (Sequenom) to iden-
tify 474 oncogenic mutations in 41 commonly mutated genes
(Table S1 for complete list) which are known to be oncogenic
or targetable to drugs. We attempted to screen and segment
gastric cancer patients according to genotypes in a large cohort
of patients.
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In this study, we examined 237 gastric adenocarcinoma samples
from which 47% (n=111) of the specimens were diffuse type in
Lauren’s classification and 24% (n=58) were EBV positive. One
hundred and seventeen patients were diagnosed at stage IV and
118 patients received palliative chemotherapy for gastric cancer.
As listed in Table 1, we screened 474 oncogenic mutations in 41
commonly mutated genes such as ABL1, AKT, APC, BRAF,
CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, FGFR, FLT3,
FNA, HRAS, IDH, JAK, KIT, KRAS, MAP2K, MET, MLH1,
MYC, NPM, NRAS, PDGFR, PIK3CA, PIK3R1, PTEN, RB1,
RET, SRC, STK11, TP53, and VHL. In 6 carcinomas, two
different somatic mutations were found concomitantly. In 27 stage
IV metastatic patients without surgical specimens available for
DNA extraction, endoscopic biopsies or biopsies from distant
metastases were used for analysis. The clinicopathologic char-
acteristics, EBV status, chemotherapy history and vital status at
the last follow-up are provided in Table 2. Molecularly targeted
agents are not widely used in gastric cancer for clinical practice
and no patients were treated with molecularly targeted agents.
Overall, 34 of 237 patients (14.4%) harbored mutated
oncogenes in their cancer tissue. Of the hotspot mutations we
screened using OncoMap v4, the most commonly mutated
oncogenes in gastric cancer were PIK3CA (n=12, 5.1%), p53
(n=11, 4.6%), APC (n=6, 2.5%), STK11 (n=5, 2.1%), CTNNB1
(n=4, 1.7%), and CDKN2A (n=2, 0.8%) (Table 3).
Discussion
In total, we found that 34 (14.4%) of 237 gastric cancer patients
harbored mutations when analyzed with mutations. PIK3CA
mutations were the most frequent (5.1%) followed by p53 (4.6%),
APC (2.5%), STK11 (2.1%), CTNNB1 (1.7%), and CDKN2A
(0.8%) in gastric cancer. In a previous high-throughput profiling of
gastric cancers using OncoMap v3, [5] percentage of samples with
mutation was 38.2%, which is slightly higher than our incidences
and the most frequent mutations were PIK3CA mutations (14.5%)
followed by KRAS genes (7.7%) and PTEN (2.5%). Recent exome
sequencing of gastric adenocarcinoma showed that samples with
microsatellite instability (MSI) had an average of 31.61 somatic
mutations per megabase of DNA, whereas the microsatellite-stable
(MSS) gastric cancer samples had an average of 3.29, a difference
of approximately tenfold. [9] Frequently mutated genes in exome
sequencing data included TP53 (36% and 73%), PIK3CA (14%
and 20%) and CTNNB1 (9% and 13.3%), [9,10] which are much
higher than we found. The limitations of OncoMap mass
spectrometric genotyping approach such as finite number of
specific point mutations that can be assayed and an inability to
detect most tumor suppressor gene mutations outside ‘‘hotspot’’
regions would be a reasonable explanation.
According to our survey, PIK3CA, found in 5.1% (12 of 237) of
cases, were the most frequent mutations and the prevalence is
similar to previous reports. [11,12] Few studies have reported on
the frequency of PIK3CA mutations in the range of 4 to 25% of
gastric cancers. [13] A relatively wide range of PIK3 mutation in
previous reports (4 to 25%) may owe to the fact that PIK3CA
mutation was studied in small cohort of archival tissue specimens
(n=12 to 94) or different stages of cancer analyzed among various
studies. Extensive clinicopathologic correlative analyses or func-
tional studies have not been actively investigated in this tumor
type, [12] rendering limited implications of PIK3CA mutations in
gastric cancer. There is an array of PIK3CA inhibitors and few of
these drugs are being tested in early phase trials for gastric cancer.
The treatment benefit from PIK3 inhibitor in PIK3CA mutated
gastric cancer should be tested in clinical trials. Of note the
frequency of PIK3CA mutations seemed higher in metastatic stage
IV disease (N=6/117, 5.1%) and stage II/III (n=5/78, 6.4%)
than stage IB (N=1/42, 2.4%). Interestingly, three PIK3CA
mutations were associated with concomitant mutations of APC or
CTNNB1 genes.
Table 1. List of genes screened for in OncoMap v4.
Gene Number of mutations
ABL1 16
AKT1 1
AKT2 2
APC 14
BRAF 50
CDK4 1
CDKN2A 11
CSF1R 7
CTNNB1 33
EGFR 51
ERBB2 9
FGFR1 2
FGFR2 6
FGFR3 8
FLT3 9
GNA11 2
GNAQ 3
GNAS 3
HRAS 16
IDH1 3
IDH2 2
JAK2 1
JAK3 3
KIT 27
KRAS 24
MAP2K1 7
MET 6
MLH1 1
MYC 6
NPM1 3
NRAS 22
PDGFRA 20
PIK3CA 23
PIK3R1 15
PTEN 15
RB1 11
RET 14
SRC 1
STK11 12
TP53 7
VHL 7
doi:10.1371/journal.pone.0038892.t001
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plays important roles in cell growth and division. [14] The
mutational site of p53 in gastric cancer is wide and the reported
incidence of p53 mutations ranges from 3.2 to 65% [15] and we
observed in 4.6% of cases using a subset of known p53 mutation
sites. The incidence of p53 mutation was significantly lower in
EBV-GC (n=1) when compared with non-EBV-GCs (n=10),
which is in line with previous reports that EBV infection might
substitute mutations of p53 during the gastric tumorigenesis. [16].
APC mutations are rare in extracolonic cancers, including
gastric carcinomas, with less than 10% of both differentiated and
undifferentiated gastric carcinomas containing such mutations.
[17] In our study, APC mutations were observed in 2.5% of cases,
which is slightly lower than previous report. [18] STK11
mutations, found in 2.1% were observed in P281L within the
kinase domain and all 5 patients with this mutation were stage IV
with extensive lymph node metastases.
In 16 cases (6.75%), we identified MLH1 V384D variant in
carcinoma samples. Further confirmation with corresponding
normal tissue confirmed this change as a germ-line variant rather
than de novo mutation in the cancer tissue. MLH1 V384D variant is
found in 2.5% and 3% of Japanese, 5.2% of Korean, and 7.7% of
Chinese, but is not observed in Western populations. [19,20] The
frequency of this variant matched in our series supporting a high
sensitivity of the OncoMap platform. We did not detect mutations
in KRAS, EGFR, PTEN, HRAS and BRAF in our study,
suggesting these mutations are rare in gastric carcinomas. These
observations are consistent with recent exome sequencing data
showing no mutations of KRAS, EGFR, HRAS and BRAF in 37
fresh gastric carcinoma samples in Asian populations. [9].
Table 2. Clinicopathologic characteristics.
Total EBV(2) EBV(+)
N=237 N=179 N=58
Gender F 69 59 10
M 168 120 48
Age mean 54.6 54.0 56.22
median 55 55 57.5
Lauren’s classification intestinal 62 44 18
diffuse 111 93 18
mixed 14 12 2
indeterminate 23 3 20
Location upper 1/3 23 16 7
mid 1/3 123 79 44
lower 1/3 76 73 3
entire stomach 15 11 4
pT stage
{ invades lamina propria or submucosa 21 5 16
invades muscularis propria or subserosa 94 57 37
penetrates serosa 71 4 67
invades adjacent structures 24 1 23
pN stage
{ no LN metastasis 45 7 38
metastasis in 1–6 LNs 62 47 15
metastasis in 7–15 LNs 41 38 3
metastasis in .15 LNs 62 60 2
Distant metastasis
{ no 170 114 56
yes 67 65 2
AJCC stage I 42 4 38
II 40 14 26
III 38 35 3
IV 117 114 3
Chemotherapy Adjuvant chemotherapy 69 51 18
Palliative chemotherapy 118 114 4
Follow-up period (days)
range 35–3754 35–3754 234–3112
Median 527 418 878
{clinical classification.
{inoperable cases.
Abbreviations, LN, lymph node; T, tumor, N, node.
doi:10.1371/journal.pone.0038892.t002
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38892Although the genomic era has rapidly arrived, whole genome
sequencing or whole exome sequencing is not available yet in the
clinic to comprehensively profile genomic aberrations. Further-
more, one of the major limitations at the moment is the limited
availability of fresh frozen tissues, especially in metastatic cancer
patients. Thus, we developed OncoMap platform which reliably
interrogates ‘‘hotspot’’ mutations using paraffin-embedded speci-
mens. Currently, OncoMap platform is the only high-throughput
platform which was tested in .1,000 paraffin-embedded tissue
specimens. [5,21,22] Until the routine use of whole genome or
whole-exome sequencing is available at a reasonable cost and
amenable to input nucleic acid from archival material, clinicians
and pathologists need to utilize paraffin embedded tissues to
interrogate multiple ‘‘hotspot’’ mutations. We screened for ‘‘hot-
spot’’ mutations in one of the largest gastric cancer cohort. The
most frequent somatic mutation in gastric cancer was PIK3CA
mutation which could be a potential therapeutic target in this
population. Another important finding is that there were no
‘‘hotspot’’ mutations in the following genes which currently have
drugs developed against: BRAF, EGFR, ERBB2, PDGFRA,
PTEN, and RET. Hence, the drugs against these ‘‘hotspot’’
somatic mutations should be of low priority for development in
gastric cancer.
With the advent of personalized genomic medicine, the
utilization as well as validity of mutation profiling using materials
from paraffin-embedded tissues widens the spectrum of patients
who can be screened for druggable targets. Our study represents
one of the largest studies which screened for the presence of
somatic mutations in gastric cancer using paraffin-embedded
tissues. Now we plan to screen for the presence of known
targetable somatic mutations in all gastrointestinal cancer patients.
Methods
Specimens
For this study, we used 237 gastric cancer samples. All primary
tumor samples were obtained from formalin-fixed paraffin-
embedded tumor specimens based on 80% cutoff for tumor
sample purity from a single institute. The quality of all DNA
samples was ensured by independent quantification and quanti-
tative PCR. The study was conducted after the approval from the
Samsung Medical Center Institutional Review Board (SMC IRB).
The primary tumor samples were all collected from Samsung
Medical Center. The study was approved by the SMC IRB for
informed consent waiver using archival tissues with retrospective
clinical data. Chi square test was used and P values ,0.05 were
considered statistically significant in this study.
Selections of Oncogene Mutations and Genotyping
Our current OncoMap v4 interrogates 474 mutations in 41
genes that are relevant for cancer (Table S1). OncoMap v4 is an
expansion of Oncomap_v1 previously described by Macconaill et
al, in 2009. [5] It interrogates frequently occurring somatic
mutations in 41 known oncogenes and tumor suppressors, many of
which are known to predict response or resistance to targeted
therapies. The somatic mutations in Oncomap v4 were selected
based on literature review and frequency of occurrence in tumor
tissue as published in the ‘Catalogue of Somatic Mutations in
Cancer’ [18] database. Genomic DNA was quantified using
Quant-iT
TM PicoGreenH dsDNA Assay Kit (Invitrogen) per
manufacturer’s protocol. 250 ng DNA was used for a mutation
analysis using Oncomap mass spectrometric genotyping based on
the Sequenom MassARRAYH technology and (Sequenom, Inc,
San Diego, CA) performed as previously described high-through-
put oncogene mutation profiling in human cancer with some
modifications. [5,22] 100 ng of tumor-derived genomic DNA was
subjected to whole genome amplification (WGA). Next, up to 18-
multiplexed PCR was performed on tumor genomic DNA to
amplify regions harboring loci of interest. After denaturation, PCR
products were incubated with the probes that anneal immediately
adjacent to the query nucleotide and mass spectrometric
genotyping using iPLEX chemistries was performed (Sequenom
Inc, San Diego, CA) extending the probes with 1 base in the
presence of chain-terminating di-deoxynucleotides that generate
allele-specific DNA products. The extension products were spotted
onto a specially designed chip and analyzed by MALDI-TOF
mass spectrometry to determine the mutation status based on the
difference in mass of the mutant and wild type base.
Next, an automated mutation calling algorithm was performed
to identify candidate mutations. Putative mutations were further
filtered by a manual review and selected for validation using multi-
base homogenous Mass-Extend (hME) chemistry with a maximum
pooling of 6 assays on the remaining 150 ng DNA of each sample.
Primers and probes used for hME validation were designed using
the Sequenom MassARRAYH Assay Design 4.0 software, applying
default multi-base extension parameters.
Only mutations found in iPLEX and confirmed by hME were
considered as ‘validated mutations’. iPLEX candidate mutations
that were not confirmed by hME were considered as invalidated
and were not reported. Examples of all detected mutations were
confirmed by standard, bidirectional Sanger sequencing.
Supporting Information
Table S1 List of Genes and Amino Acid changes
screened for in Oncomap_v4.
(DOC)
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Table 3. Frequency of mutations.
Gene Amino acid N % EBV(+) EBV(2) P value
PIK3CA E542K 6 2.53 3 3
E545K 5 2.11 2 3 0.076
E545G 1 0.42 1 0
p53 R306* 4 1.69 0 4
R175H 3 1.27 1 2
R273C 3 1.27 0 3 0.303
R248Q 1 0.42 0 1
APC Q1378* 5 2.11 2 3
T1556fs*3 1 0.42 0 1 0.636
STK11 P281L 5 2.11 1 4 –
CTNNB1 D32N 2 0.84 2 0
G34E 1 0.42 1 0 0.046
S37F 1 0.42 0 1
CDKN2A R58* 2 0.84 1 1 0.245
N, total number of samples with mutation.
doi:10.1371/journal.pone.0038892.t003
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